Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma

J Clin Endocrinol Metab. 2024 Apr 25:dgae283. doi: 10.1210/clinem/dgae283. Online ahead of print.


Introduction: Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a first-in-class, highly selective, and potent small molecule RET kinase inhibitor that has demonstrated marked and durable anti-tumor activity in diverse RET-activated solid tumors in the LIBRETTO-001 study (NCT03157128).

Methods: We describe the first six pheochromocytoma cases treated with selpercatinib in the LIBRETTO-001 study.

Results: Of the six patients (one sporadic and five reported as part of MEN2 syndromes) in this case report, four had a partial response/complete response and two had stable disease per independent review committee. Treatment duration ranged from 9.2 months to more than 56.4 months. The safety profile of treatment was consistent with selpercatinib in other indications.

Conclusion: These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.

Keywords: RET; pheochromocytoma; selpercatinib.

Associated data